Fulgent Genetics, Inc.
Fulgent Genetics, Inc. (FLGT) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
flgt · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Fulgent Genetics, Inc. (FLGT) measures how much investors pay for each dollar of the company's trailing earnings. FLGT's current PE ratio of N/A is calculated by dividing its stock price of $18.70 by its TTM earnings per share of -$2.39.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2014 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 3 fiscal years · Front-end computedMinQ1 · 25%5.8x
MedianQ3 · 75%6.3x
Max
At N/A, FLGT's current P/E is lower than in 0% of its annual fiscal year readings over the past 3 years — historically low.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Medical - Diagnostics & Research · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Fulgent Genetics, Inc.You FLGT | $531M | N/A | — | -$2.39 |
 Arvinas, Inc. ARVN | $476M | N/A | — | -$1.24 |
 Anavex Life Sciences Corp. AVXL | $238M | N/A | — | -$0.54 |
 Butterfly Network, Inc. BFLY | $1.2B | N/A | — | -$0.31 |
 CareDx, Inc CDNA | $1.1B | N/A | — | -$0.40 |
 Castle Biosciences, Inc. CSTL | $616M | N/A | — | -$0.83 |
 DarioHealth Corp. DRIO | $52M | N/A | — | -$0.84 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-1.97 | — | |
2024-12-31 FY2024 | — | $-1.41 | — | |
2023-12-31 FY2023 | — | $-5.63 | — | |
2022-12-31 FY2022 | 6.25x | $4.76 | +7.2% | |
2021-12-31 FY2021 | 5.83x | $17.25 | +5.7% | |
2020-12-31 FY2020 | 5.52x | $9.44 | — | |
2019-12-31 FY2019 | — | $-0.02 | — | |
2018-12-31 FY2018 | — | $-0.31 | — | |
2017-12-31 FY2017 | — | $-0.14 | — | |
2016-12-31 FY2016 | — | $-0.30 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Fulgent Genetics, Inc. (FLGT) measures how much investors pay for each dollar of the company's trailing earnings. FLGT's current PE ratio of N/A is calculated by dividing its stock price of $18.70 by its TTM earnings per share of -$2.39.
Frequently asked questions
FLGT pe ratio · 6 questionsFLGT's current PE ratio is N/A as of 2026-06-08, based on a stock price of $18.70 and TTM EPS of -$2.39. Data sourced from Financial Modeling Prep via FLGT's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Fulgent Genetics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08